Stocktwits on MSN20h
Sarepta Therapeutics Temporarily Halts Three Clinical Studies Of Elevidys: Retail Is Dull While Stock Drops
Shares of Sarepta Therapeutics, Inc. (SRPT) traded over 2% lower in afternoon trade on Friday after the company said it has ...
Roche To Start Phase 3 Study For Alzheimer's Prospect This Year After New Data From Phase 2
Roche Holdings AG (OTC:RHHBY) on Thursday presented new data at the AD/PD 2025 International Conference on Alzheimer’s and ...
Devdiscourse17h
Health Sector Reels Under Political and Market Pressure
Recent developments in the health sector include Indian pharmaceutical stocks' dip due to tariff threats, mass FDA layoffs ...
Ousted vaccine chief says RFK Jr’s team sought data to justify anti-science stance
The top vaccine regulator ousted by Robert F. Kennedy Jr said the health secretary’s team has sought non-existent data to ...
Investor's Business Daily on MSN2h
Eli Lilly, Novo Stocks Dive After Medicare Excludes Weight-Loss Drugs
The Trump administration finalized new Medicare and Medicaid policies late Friday, but left out a key provision that would have expanded coverage for weight-loss drugs. In response, Eli Lilly stock ...
Precision Medicine Online23h
Sarepta Pauses EU Elevidys Trials, Data Monitoring Panel Confirms Favorable Risk-Benefit Profile
The firm said the clinical trial pause is temporary as an independent data monitoring committee finalizes its analysis for submission to regulators.